The Association Between Taxane Use and Lacrimal Disorders

References

• Fortes BH, Liou H, Dalvin LA. Ophthalmic adverse effects of taxanes: the Mayo Clinic experience. Eur J Ophthalmol. 2022;32(1):602–611. doi:10.1177/1120672120969045.
   PubMed Web of Science ®Google Scholar
• Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol. 2013;31(17):2123–2127. doi:10.1200/JCO.2012.45.6574.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98(3):504–507. doi:10.1002/cncr.11527.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do KA, Rivera E. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006;24(22):3619–3622. doi:10.1200/JCO.2005.04.4453.
   PubMed Web of Science ®Google Scholar
• Sodhi M, Yeung SN, Maberley D, Mikelberg F, Etminan M. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy. JAMA Ophthalmol. 2022;140(9):880–884. doi:10.1001/jamaophthalmol.2022.3026.
   PubMed Web of Science ®Google Scholar
• Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026. doi:10.1038/sdata.2016.26.
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res. 1996;2(5):837–842.
   PubMed Web of Science ®Google Scholar
• Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29(2):117–125. doi:10.1185/03007995.2012.756393.
   PubMed Web of Science ®Google Scholar
• Gorimanipalli B, Khamar P, Sethu S, Shetty R. Hormones and dry eye disease. Indian J Ophthalmol. 2023;71(4):1276–1284. doi:10.4103/IJO.IJO_2887_22.
   PubMedGoogle Scholar
• Sipkova Z, Vonica O, Olurin O, Obi EE, Pearson AR. Assessment of patient-reported outcome and quality of life improvement following surgery for epiphora. Eye. 2017;31(12):1664–1671. doi:10.1038/eye.2017.120.
   PubMed Web of Science ®Google Scholar
• Shin JH, Kim YD, Woo KI, Korean Society of Ophthalmic Plastic and Reconstructive Surgery (KSOPRS). Impact of epiphora on vision-related quality of life. BMC Ophthalmol. 2015;15:6. doi:10.1186/1471-2415-15-6.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Hortobagyi G, Esteva F, Valero V, Ahmadi MA, Booser D, Ibrahim N, Delpassand E, Arbuckle R. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002;13(2):218–221. doi:10.1093/annonc/mdf036.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002;109(6):1188–1191. doi:10.1016/s0161-6420(02)00989-2.
   PubMed Web of Science ®Google Scholar
• Mansur C, Pfeiffer ML, Esmaeli B. Evaluation and management of chemotherapy-induced epiphora, punctal and canalicular stenosis, and nasolacrimal duct obstruction. Ophthalmic Plast Reconstr Surg. 2017;33(1):9–12. doi:10.1097/IOP.0000000000000745.
   PubMed Web of Science ®Google Scholar
• Steele EA. Conjunctivodacryocystorhinostomy with Jones tube: a history and update. Curr Opin Ophthalmol. 2016;27(5):439–442. doi:10.1097/ICU.0000000000000287.
   PubMed Web of Science ®Google Scholar
• Vicinanzo MG, Allamneni C, Compton CJ, Long JA, Nabavi CB. The prevalence of air regurgitation and its consequences after conjunctivodacryocystorhinostomy and dacryocystorhinostomy in continuous positive airway pressure patients. Ophthalmic Plast Reconstr Surg. 2015;31(4):269–271. doi:10.1097/IOP.0000000000000280.
   PubMed Web of Science ®Google Scholar
• Eisenbach N, Karni O, Sela E, Nemet A, Dror A, Levy E, Kassif Y, Ovadya R, Ronen O, Marshak T. Conjunctivodacryocystorhinostomy (CDCR) success rates and complications in endoscopic vs. non-endoscopic approaches: a systematic review. Int Forum Allergy Rhinol. 2021;11(2):174–194. doi:10.1002/alr.22668.
   PubMed Web of Science ®Google Scholar
• Chang M, Lee H, Park M, Baek S. Long-term outcomes of endoscopic endonasal conjunctivodacryocystorhinostomy with Jones tube placement: a thirteen-year experience. J Craniomaxillofac Surg. 2015;43(1):7–10. doi:10.1016/j.jcms.2014.10.001.
   PubMed Web of Science ®Google Scholar
• Tsalic M, Gilboa M, Visel B, Miller B, Haim N. Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity. Med Oncol. 2006;23(1):57–61. doi:10.1385/MO:23:1:57.
   PubMed Web of Science ®Google Scholar
• Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength. Hosp Pharm. 2021;56(3):152–158. doi:10.1177/0018578719882323.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–523. doi:10.1002/pds.1001.
   PubMed Web of Science ®Google Scholar
• Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, Bell C, Bouri K, Bright-Ponte SJ, Botsis T, et al. Data mining at FDA – White Paper. U.S. Food & Drug Administration; August 2018. Available from: https://www.fda.gov/science-research/data-mining/data-mining-fda-white-paper.
   Google Scholar